Hansa Biopharma AB (OSTO:HNSA) Ending Cash Position : kr541.5 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Ending Cash Position?

Hansa Biopharma AB's Ending Cash Position for the quarter that ended in Mar. 2024 was kr541.5 Mil.

Hansa Biopharma AB's quarterly Ending Cash Position declined from Sep. 2023 (kr908.2 Mil) to Dec. 2023 (kr732.1 Mil) and declined from Dec. 2023 (kr732.1 Mil) to Mar. 2024 (kr541.5 Mil).

Hansa Biopharma AB's annual Ending Cash Position increased from Dec. 2021 (kr651.3 Mil) to Dec. 2022 (kr1,496.2 Mil) but then declined from Dec. 2022 (kr1,496.2 Mil) to Dec. 2023 (kr732.1 Mil).

Hansa Biopharma AB Ending Cash Position Historical Data

The historical data trend for Hansa Biopharma AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Ending Cash Position Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

181.70

1,139.36

651.34

1,496.18

732.06

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															1,286.82	1,102.51	908.18	732.06	541.47

Hansa Biopharma AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hansa Biopharma AB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1496.179	+	-764.119
	=	732.1

Hansa Biopharma AB's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	732.06	+	-190.595
	=	541.5

Hansa Biopharma AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines